Ken Griffin Cogent Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$8.24 - $11.48 $13,184 - $18,368	1,600 Added 4.37%	38,200 $412,000
Q2 2024 Aug 14, 2024	BUY	$6.01 - $9.04 $52,888 - $79,551	8,800 Added 31.65%	36,600 $308,000
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $81,906 - $168,674	-18,700 Reduced 40.22%	27,800 $186,000
Q4 2023 Feb 14, 2024	BUY	$4.06 - $10.08 $107,995 - $268,128	26,600 Added 133.67%	46,500 $273,000
Q3 2023 Nov 14, 2023	BUY	$9.69 - $13.34 $38,760 - $53,360	4,000 Added 25.16%	19,900 $194,000
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.24 $28,565 - $38,396	2,900 Added 22.31%	15,900 $188,000
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $239,955 - $370,450	-23,900 Reduced 64.77%	13,000 $140,000
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $118,215 - $164,724	-11,100 Reduced 23.13%	36,900 $426,000
Q3 2022 Nov 14, 2022	SELL	$9.39 - $16.99 $100,473 - $181,792	-10,700 Reduced 18.23%	48,000 $716,000

171

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $600M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.